Invesco Ltd. boosted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 6.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,160,988 shares of the company's stock after acquiring an additional 74,324 shares during the quarter. Invesco Ltd. owned 1.42% of IDEXX Laboratories worth $479,999,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also recently modified their holdings of the company. Insight Wealth Strategies LLC increased its holdings in shares of IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock worth $4,174,000 after buying an additional 7,041 shares during the period. Geode Capital Management LLC lifted its stake in shares of IDEXX Laboratories by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company's stock valued at $1,138,732,000 after purchasing an additional 40,349 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at $1,263,000. Sax Wealth Advisors LLC boosted its stake in IDEXX Laboratories by 76.3% during the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock worth $590,000 after acquiring an additional 617 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its position in shares of IDEXX Laboratories by 11.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock worth $3,199,000 after purchasing an additional 800 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.
Insider Transactions at IDEXX Laboratories
In related news, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company's stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.11% of the company's stock.
IDEXX Laboratories Price Performance
Shares of NASDAQ IDXX traded up $9.07 during mid-day trading on Monday, hitting $400.01. 175,356 shares of the company's stock traded hands, compared to its average volume of 615,166. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $548.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The company's 50-day moving average is $428.03 and its two-hundred day moving average is $433.60. The company has a market capitalization of $32.42 billion, a P/E ratio of 37.49, a PEG ratio of 3.41 and a beta of 1.50.
Analyst Ratings Changes
IDXX has been the topic of several recent analyst reports. Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday. Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Finally, Piper Sandler lifted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research note on Monday, February 10th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, IDEXX Laboratories currently has an average rating of "Moderate Buy" and an average price target of $523.75.
Read Our Latest Stock Analysis on IDXX
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
